missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ CD62L (L-Selectin) Monoclonal Antibody (DREG-56 (DREG56)), Brilliant Violet™ 650, eBioscience™, Invitrogen™
Beskrivning
The human CD62L is a 74-95 kDa glycoprotein member of the selectin family of adhesion receptors. L-Selectin is comprised of an aminoterminal C-type lectin binding domain, an epidermal growth factor-like domain, two short consensus repeat (SCR) sequences homologous to those found in complement binding proteins, a short spacer region, a transmembrane region and a short cytoplasmic region. Human CD62L (L-Selectin) is constitutively expressed on all classes of leukocytes including lymphocytes (except a substantial population of memory T cells), monocytes and polymorphonuclear cells.
Specifikationer
Specifikationer
| Antigen | CD62L (L-Selectin) |
| Anwendungen | Flow Cytometry |
| Klassifikation | Monoclonal |
| Klon | DREG-56 (DREG56) |
| Konzentration | 5 μL/Test |
| Konjugat | Brilliant Violet 650 |
| Zusammensetzung | PBS with BSA and 0.09% sodium azide; pH 7.2 |
| Gen | SELL |
| Gen-Zugriffsnummer | P14151 |
| Gen-Alias | A.11; AI528707; CD62 antigen-like family member L; CD62L; gp90-MEL; hLHRc; LAM1; LAM-1; LECAM1; LECAM-1; LEU8; Leu-8; Leukocyte adhesion molecule 1; leukocyte surface antigen Leu-8; Leukocyte-endothelial cell adhesion molecule 1; LNHR; LSEL; L-selectin; Ly22; Ly-22; LYAM1; Lyam-1; Ly-m22; Lymph node homing receptor; lymphocyte adhesion molecule 1; lymphocyte antigen 22; Lymphocyte surface MEL-14 antigen; pln homing receptor; PLNHR; SELE; selectin E (endothelial adhesion molecule 1); selectin L; selectin L (lymphocyte adhesion molecule 1); selectin, lymphocyte; Sell; TQ1 |
| Visa mer |
Produkttitel
Genom att klicka på Skicka bekräftar du att du kan bli kontaktad av Fisher Scientific angående feedbacken du har lämnat i detta formulär. Vi kommer inte att dela din information för andra ändamål. All kontaktinformation som tillhandahålls ska också underhållas i enlighet med vår Sekretesspolicy.
Hittar du en möjlighet till förbättring?